Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Farletuzumab ecteribulin - Eisai Inc

Next Previous
Drug Profile

Farletuzumab ecteribulin - Eisai Inc

Alternative Names: Eribulin/farletuzumab antibody drug conjugate - Morphotek; Farletuzumab/eribulin ADC; MORAb-202

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Morphotek
  • Developer Bristol-Myers Squibb; Eisai Inc
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Drug conjugates; Furans; Immunoconjugates; Ketones; Macrocyclic compounds; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Endometrial cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV, Infusion)
  • 12 Aug 2024 Bristol-Myers Squibb terminates a phase II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US, Australia, Belgium, Chile, Spain, and France (IV) due to the business objectives have changed (NCT05577715)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top